24 **Y-1580 Investment Opportunities in API Bulk Drugs & Intermediates** Manufacturing Unit. Govt Announces Rs. 13,760-Cr **Package to Boost API & Medical Device Production** 

in India.



# **Active Pharmaceutical Ingredient (API)**

API (Active <u>Pharmaceutical</u> Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.





# **Role of Government Towards API**

The coronavirus outbreak disrupting supply of active <u>pharmaceutical</u> ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of <u>bulk drugs</u> and medical devices in the country and their exports.

On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively.





The Cabinet also approved a scheme on promotion of bulk <u>drug</u> parks for financing common infrastructure facilities in three bulk <u>drug</u> parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc.

The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/<u>drug</u> intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years.





Financial incentive will be given to eligible manufacturers of identified 53 critical bulk <u>drugs</u> on their incremental sales over the base year (2019-20) for a period of 6 years.

Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are <u>chemical</u> synthesis based bulk drugs.

Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for <u>chemical</u> synthesis based bulk drugs.

Related Projects: - <u>Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug</u> <u>Intermediates,</u>





The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years.

The drug industry has welcomed the incentives offered by the government to promote API units in India.

Besides <u>APIs</u>, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore.

The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years.





Medical device is a growing sector and its potential for growth is the highest among all sectors in the <u>healthcare</u> market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices.

Related Books: - <u>Pharmaceutical</u>, <u>Drugs</u>, <u>Proteins</u> <u>Technology</u> <u>Handbooks</u>





# <u>Union Cabinet Scheme on Promotion of Bulk Drug</u> <u>Parks</u>

• The scheme on Promotion of Bulk <u>Drug</u> Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.





• Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years.

Related videos: - <u>Manufacturing Business Ideas in Pharmaceutical</u> <u>Industry</u>

Manufacturing of Pharmaceutical Bulk Drugs and Medicine

**Pharmaceutical Pellets and Granules** 

**Pharmaceutical Manufacturing Unit** 

Indian Pharma Industry: An Investment Opportunity

**Manufacturing Business Ideas in Pharmaceutical Industry** 





# **Details:**

#### **Promotion of Bulk Drug Parks**

• Decision is to develop 3 mega Bulk Drug parks in <u>India</u> in partnership with States.

- Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
- Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.
- A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.





# **Production Linked Incentive Scheme**

- Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
- Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are <u>chemical</u> synthesis based bulk drugs.
- Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for <u>chemical</u> synthesis based bulk drugs.
- A sum of Rs. 6,940 crore has been approved for next 8 years.





### **List of APIs Products Identified**

- 1) Amoxicillin
- 2) Azithromycin
- 3) Erythromycin Stearate/Estolate
- 4) Ceftriaxone
- 5) Cefoperazone
- 6) Cefixime
- 7) Cephalexin
- 8) Piperacillin Tazobactam
- 9) Sulbactam
- 10) Dexamethasone



- 11) Prednisolone
- 12) Metformin
- 13) Gabapentin
- 14) Rifampicin
- 15) Vitamin B1
- 16) Vitamin B6
- 17) Clindamycin phosphate
- 18) Clindamycin HCL
- 19) Streptomycin
- 20) Neomycin
- 21) Gentamycin
- 22) Doxycycline



- 23) Potassium clavulanate
- 24) Oxytetracycline
- 25) Tetracycline
- 26) Clarithromycin
- 27) Betamethasone
- 28) Ciprofloxacin
- 29) Losartan
- 30) Telmisartan
- 31) Artesunate



- 32) Norfloxacin
- 33) Ofloxacin
- 34) Metronidazole
- 35) Sulfadiazine
- 36) Levofloxacin
- 37) Meropenem
- 38) <u>Paracetamol</u>
- 39) Tinidazole
- 40) Ornidazole
- 41) Ritonavir
- 42) Diclofenac Sodium
- 43) Aspirin



- 44) Levetiracetam
- 45) Carbidopa
- 46) Levodopa
- 47) Carbamazepine
- 48) Oxcarbazepine
- 49) Valsartan
- 50) Olmesartan
- 51) Atorvastatin
- 52) Acyclovir
- 53) Lopinavir



# **Market in India**

The Indian <u>pharmaceutical industry</u> is ranked third in the world in terms of production volume and 13th in terms of domestic consumption value. The Indian pharmaceutical industry size is estimated at US\$25 billion in 2015. Formulations account for 65% and bulk drugs for the balance 35% in value terms. The industry is expected to reach US\$55 billion by 2020. Bulk drug exports are expected to grow the fastest at 14-16% CAGR due to the growing demand of generic products and rising cost pressures that innovators face. Formulation exports are also expected to grow at 14-16% CAGR.





<u>API</u> manufacturers in India are making efforts to strengthen their marketing capacity in the regulated markets by improving production yields, modifying production processes, and increasing sales in the international markets. More than 30% of the APIs manufactured in India are exported to countries such as US, UK, Japan, etc. The total production market of <u>API</u> in India was valued at approximately US\$ 11 Billion in FY 2016. This market is forecasted to grow at a CAGR of around 9% during the period of FY 2016–FY 2022. Of the total domestic consumption, approximately 32% was imported. Of the total imports, China alone accounts for 57-60% of the APIs imported by India. The remaining imports are from countries such as Italy, Germany, Malaysia, and others. These facts indicate that there is plentiful scope for the domestic API market to grow, if the manufacturers are able to produce the required amount of APIs on their own, rather than importing it from other countries.



## **Indian API Domestic Consumption**

The Indian <u>API</u> domestic consumption market will grow at a CAGR of around 10% from FY 2016 to FY 2022. Furthermore, the government is also taking various initiatives, such as allocating lands in various states for the development of API Mega Parks, increased investment in R&D, etc. to boost the industry. These initiatives will further propel the growth of the Indian API industry, as well as the domestic market for the APIs.

#### Related Videos: - <u>https://bit.ly/2XVNXsY</u>





# **Key Players**

Sun Pharma, Dr. Reddy's, Cipla, Aurobindo Pharma, Lupin, etc., are being lured to increase their investment in the Indian API industry by providing them various lucrative offers.





# Major Queries/Questions Answered in the Report?

- 1. What is Active Pharmaceutical Ingredient (API) Manufacturing industry ?
- 2. How has the Active Pharmaceutical Ingredient (API) Manufacturing industry performed so far and how will it perform in the coming years ?
- 3. What is the Project Feasibility of Active Pharmaceutical Ingredient (API) Manufacturing Plant ?
- 4. What are the requirements of Working Capital for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant ?



**5. What is the structure of the Active Pharmaceutical Ingredient (API) Manufacturing Business and who are the key/major players ?** 

- 6. What is the total project cost for setting up Active Pharmaceutical Ingredient (API) Manufacturing Business?
- 7. What are the operating costs for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant?
- 8. What are the machinery and equipment requirements for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant ?



9. Who are the Suppliers and Manufacturers of Plant & Machinery for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant ?

- 10. What are the requirements of raw material for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant ?
- 11. Who are the Suppliers and Manufacturers of Raw materials for setting up Active Pharmaceutical Ingredient (API) Manufacturing Business?
- 12. What is the Manufacturing Process of Active Pharmaceutical Ingredient (API)?



13. What is the total size of land required for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant?

14. What will be the income and expenditures forActivePharmaceutical Ingredient (API) Manufacturing Business?

- **15. What are the Projected Balance Sheets of Active Pharmaceutical Ingredient (API) Manufacturing plant ?**
- 16. What are the requirement of utilities and overheads for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant?
- 17. What is the Built up Area Requirement and cost for setting up Active Pharmaceutical Ingredient (API) Manufacturing Business?



- 18. What are the Personnel (Manpower) Requirements for setting up Active Pharmaceutical Ingredient (API) Manufacturing Business?
- **19. What are Statistics of Import & Export for Active Pharmaceutical Ingredient (API)?**
- **20.** What is the time required to break-even of Active Pharmaceutical Ingredient (API) Manufacturing Business?
- 21. What is the Break-Even Analysis of Active Pharmaceutical Ingredient (API) Manufacturing plant?
- 22. What are the Project financials of Active Pharmaceutical Ingredient (API) Manufacturing Business?



23. What are the Profitability Ratios of Active Pharmaceutical Ingredient (API) Manufacturing Project?

24. What is the Sensitivity Analysis-Price/Volume of Active Pharmaceutical Ingredient (API) Manufacturing plant?

25. What are the Projected Pay-Back Period and IRR of Active Pharmaceutical Ingredient (API) Manufacturing plant?

26. What is the Process Flow Sheet Diagram of Active Pharmaceutical Ingredient (API) Manufacturing project?



27. What are the Market Opportunities for setting up Active Pharmaceutical Ingredient (API) Manufacturing plant?

28. What is the Market Study and Assessment for setting up Active Pharmaceutical Ingredient (API) Manufacturing Business?

29. What is the Plant Layout for setting up Active Pharmaceutical Ingredient (API) Manufacturing Business?



# Table of Contentsof theProject Report



#### **Our Detailed Project Report contains**

- Introduction
- Properties
- Uses & Applications
- List of Plant & Machineries
- Miscellaneous Items and Accessories
- Instruments, Laboratory Equipments and Accessories
- Electrification, Electric Load and Water
- Maintenance, Suppliers/Manufacturers of Plant and Machineries
- Process of Manufacture
- Flow Sheet Diagram
- List of Raw Materials
- Availability of Raw Materials
- Requirement of Staff & Labour
- Skilled & Unskilled Labour
- Requirement of Land Area
- Built up Area
- Plant Layout.



#### > Along with financial details as under:

### Assumptions for Profitability workings

- Plant Economics
- Production Schedule
- Land & Building
- Factory Land & Building
- Site Development Expenses

#### Plant & Machinery

- Indigenous Machineries
- Other Machineries (Miscellaneous, Laboratory etc.)

#### Other Fixed Assets

- Furniture & Fixtures
- Pre-operative and Preliminary Expenses
- Technical Knowhow
- Provision of Contingencies



#### **Working Capital Requirement Per Month**

- Raw Material
- Packing Material
- Lab & ETP Chemical Cost
- Consumable Store

## **Overheads Required Per Month And Per Annum**

- Vtilities & Overheads (Power, Water and Fuel Expenses etc.)
- Royalty and Other Charges
- Selling and Distribution Expenses
- Salary and Wages
- Turnover Per Annum
- Share Capital
- Equity Capital
- Preference Share Capital

### Annexure 1 Cost of Project and Means of Finance

- **Annexure 2 Profitability and Net Cash Accruals**
- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items



#### **Gross Profit**

- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals

#### **Annexure 3 :: Assessment of Working Capital requirements**

- Current Assets
- Gross Working. Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process

**Annexure 4 :: Sources and Disposition of Funds** 

#### **Annexure 5 :: Projected Balance Sheets**

- ROI (Average of Fixed Assets)
- > RONW (Average of Share Capital)
- ROI (Average of Total Assets)



#### **Annexure 6 :: Profitability ratios**

- > D.S.C.R
- Earnings Per Share (EPS)
- Debt Equity Ratio

#### Annexure 7 :: Break-Even Analysis

- Variable Cost & Expenses
- Semi-Var./Semi-Fixed Exp.
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- ≻ B.E.P

#### Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume

- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP



#### **Annexure 12 :: Shareholding Pattern and Stake Status** Equity Capital Preference Share Capital

#### **Annexure 13 :: Quantitative Details-Output/Sales/Stocks**

- Determined Capacity P.A of Products/Services
- Achievable Efficiency/Yield % of Products/Services/Items
- Net Usable Load/Capacity of Products/Services/Items
- Expected Sales/ Revenue/ Income of Products/ Services/ Items

#### **Annexure 14 :: Product wise domestic Sales Realisation**

**Annexure 15 :: Total Raw Material Cost** 

**Annexure 16 :: Raw Material Cost per unit** 

**Annexure 17 :: Total Lab & ETP Chemical Cost** 

Annexure 18 :: Consumables, Store etc.



#### **Annexure 19 :: Packing Material Cost**

**Annexure 20 :: Packing Material Cost Per Unit** 

**Annexure 21 :: Employees Expenses** 

**Annexure 22 :: Fuel Expenses** 

**Annexure 23 :: Power/Electricity Expenses** 

**Annexure 24 :: Royalty & Other Charges** 

Annexure 25 :: Repairs & Maintenance Exp.

**Annexure 26 :: Other Mfg. Expenses** 

**Annexure 27 :: Administration Expenses** 

**Annexure 28 :: Selling Expenses** 



**Annexure 29 :: Depreciation Charges – as per Books (Total)** 

**Annexure 30 :: Depreciation Charges – as per Books (P & M)** 

Annexure 31 :: Depreciation Charges - As per IT Act WDV (Total)

Annexure 32 :: Depreciation Charges - As per IT Act WDV (P & M)

**Annexure 33 ::Interest and Repayment - Term Loans** 

**Annexure 34:: Tax on Profits** 

**Annexure 35 :: Projected Pay-Back Period And IRR** 



# **Project Financials**

•	Project at a Glance	Annexure
•	Assumptions for Profitability workings	1
•	Plant Economics	2
•	Production Schedule	3
•	Land & Building Factory Land & Building Site Development Expenses	4



Plant & Machinery......5 **Indigenous Machineries Other Machineries (Miscellaneous, Laboratory etc.) Furniture & Fixtures Pre-operative and Preliminary Expenses Technical Knowhow Provision of Contingencies** Working Capital Requirement Per Month......7 **Raw Material Packing Material** Lab & ETP Chemical Cost **Consumable Store** 



•	<b>Overheads Required Per Month and Per Annum</b>
	Utilities & Overheads (Power, Water and Fuel Expenses etc.)
	Royalty and Other Charges
	Selling and Distribution Expenses

•	Salary and Wages	 9

•	Turnover	Per	Annum		0
---	----------	-----	-------	--	---

Share Capital.....11

Equity Capital Preference Share Capital



- Annexure 1 :: Cost of Project and Means of Finance
- Annexure 2 :: Profitability and Net Cash Accruals
- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items
- Gross Profit
- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals



#### • Annexure 3 :: Assessment of Working Capital requirements

- Current Assets
- Gross Working Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process

#### • Annexure 4 :: Sources and Disposition of Funds





#### • Annexure 5 :: Projected Balance Sheets

- ROI (Average of Fixed Assets)
- RONW (Average of Share Capital)
- ROI (Average of Total Assets)
- Annexure 6 :: Profitability Ratios
- **D.S.C.R**
- Earnings Per Share (EPS)
- Debt Equity Ratio



• Annexure 7 :: Break-Even Analysis

- Variable Cost & Expenses
- Semi-Variable/Semi-Fixed Expenses
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- **B.E.P**





• Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume

- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP



- Annexure 12 :: Shareholding Pattern and Stake Status
- Equity Capital
- Preference Share Capital
- Annexure 13 :: Quantitative Details-Output/Sales/Stocks
- Determined Capacity P.A of Products/Services
- Achievable Efficiency/Yield % of Products/Services/Items
- Net Usable Load/Capacity of Products/Services/Items
- Expected Sales/ Revenue/ Income of Products/ Services/ Items



- Annexure 14 :: Product wise Domestic Sales
   Realisation
- Annexure 15 :: Total Raw Material Cost
- Annexure 16 :: Raw Material Cost per unit

•••

•••

- Annexure 17
- Annexure 18 ::
- Annexure 19

- **Total Lab & ETP Chemical Cost**
- : Consumables, Store etc.
  - Packing Material Cost
- Annexure 20 :: Packing Material Cost Per Unit



- Annexure 21
- Annexure 22 ::
- Annexure 23
- Annexure 24
- Annexure 25
- Annexure 26
- Annexure 27
- Annexure 28

- **::** Employees Expenses
- : Fuel Expenses

::

::

::

::

::

- **Power/Electricity Expenses**
- **Royalty & Other Charges** 
  - **Repairs & Maintenance Expenses**
  - **Other Manufacturing Expenses**
  - Administration Expenses
- :: Selling Expenses



- Annexure 29 :: Depreciation Charges as per Books (Total)
  Annexure 30 :: Depreciation Charges as per Books (P &
- Annexure 30 :: Depreciation Charges as per Books (P & M)
- Annexure 31 :: Depreciation Charges as per IT Act WDV (Total)
- Annexure 32 :: Depreciation Charges as per IT Act WDV (P & M)
- Annexure 33 :: Interest and Repayment Term Loans
- Annexure 34 :: Tax on Profits
- Annexure 35 :: Projected Pay-Back Period and IRR



## **Reasons for Buying our Report:**

- This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, market potential of the product and reasons for investing in the product
- This report provides vital information on the product like it's characteristics and segmentation
- This report helps you market and place the product correctly by

identifying the target customer group of the product



• This report helps you understand the viability of the project by disclosing details like machinery required, project costs and snapshot of other project financials

- The report provides a glimpse of government regulations applicable on the industry
- The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decisions





report



## **Scope of the Report**

The report titled "Market Survey cum Detailed Techno Economic Feasibility Report on Active Pharmaceutical Ingredient (API)." provides an insight into Active Pharmaceutical Ingredient (API) market in India with focus on uses and applications, Manufacturing Process, Process Flow Sheets, Plant Layout and Project Financials of Active Pharmaceutical Ingredient (API) project. The report assesses the market sizing and growth of the Indian Active Pharmaceutical Ingredient (API) Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line. And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:



- Good Present/Future Demand
- Export-Import Market Potential
- Raw Material & Manpower Availability
- Project Costs and Payback Period

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in the Active Pharmaceutical Ingredient (API) sector in India along with its business prospects. Through this report we have identified Active Pharmaceutical Ingredient (API) project as a lucrative investment avenue.



## Tags

#APIBusiness #ActivePharmaceuticalIngredient #API #startupindia #ceftriaxone #Amoxicillin #azithromycint #ErythromycinStearate #cefixime #amoxicillin #cefoperazone #cephalexin #doxycycline #ciprofloxacin #clindamycin #metronidazole #azithromycine #Piperacillin #tazobactam #sulbactam #dexamethasone #prednisolone #Metformin #Streptomycin #Gabapentin #clindamycin #Clindamycin #Neomycin #Doxycycline #Potassiumclavulanate #Oxytetracycline #Gentamycin #Tetracycline #Clarithromycin #Betamethasone #Ciprofloxacin #Losartan #Telmisartan #Artesunate #Norfloxacin #Ofloxacin #Metronidazole **#Sulfadiazine** 



#Levofloxacin #Meropenem #Paracetamol #Tinidazole #Ornidazole #Ritonavir #Diclofenac Sodium #Aspirin #Levetiracetam #Carbidopa #Levodopa #Carbamazepine #Oxcarbazepine #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbusiness #covid19 #covidsmallbusiness



# Niir Project Consultancy Services (NPCS) can provide Detailed Project Report on Active Pharmaceutical Ingredient (API)

## See more Project Reports & Profiles BOOKS







## Take a look at Niir Project Consultancy Services on #Street View https://goo.gl/VstWkd

Locate us on

**Google Maps** 

https://goo.gl/maps/BKkUtq9gevT2



## **OUR CLIENTS**

Our inexhaustible Client list includes public-sector companies, Corporate Houses, Government undertaking, individual entrepreneurs, NRI, Foreign investors, non-profit organizations and educational institutions from all parts of the World. The list is just a glimpse of our esteemed & satisfied Clients.

## Click here to take a look https://goo.gl/G3ICjV



#### Select and Choose the Right Business Startup for You

#### (Instant Online Project Identification and Selection)

Finding the right startup business is one of the most popular subject today. Starting a business is no easy endeavor, but the time, effort, and challenges can be worth it if you succeed. To give yourself the best chance to be successful, take your time to carefully find the right business for you. We, at NPCS, endeavor to make business selection a simple and convenient step for any entrepreneur/startup. Our expert team, by capitalizing on its dexterity and decade's long experience in the field, has created a list of profitable ventures for entrepreneurs who wish to diversify or venture. The list so mentioned is updated regularly to give you a regular dose of new emerging opportunities.

Visit: <u>https://www.entrepreneurindia.co/project-identification</u>



### **Download Complete List of Project Reports:**

#### Detailed Project Reports

Visit:- <u>https://www.entrepreneurindia.co/complete-project-list</u>

NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our Market Survey cum Detailed Techno Economic Feasibility Report provides an insight of market in India. The report assesses the market sizing and growth of the Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.



And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- Good Present/Future Demand
- Export-Import Market Potential
- Raw Material & Manpower Availability
- Project Costs and Payback Period

The detailed project report covers all aspect of business, from analyzing the market, confirming availability of various necessities such as Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule,



Working Capital Requirement, uses and applications, Plant Layout, Project Financials, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis. The DPR (Detailed Project Report) is formulated by highly accomplished and experienced consultants and the market research and analysis are supported by a panel of experts and digitalized data bank.

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in India along with its business prospects......<u>Read more</u>



## **Contact us**

## **NIIR PROJECT CONSULTANCY SERVICES**

- 106-E, Kamla Nagar, Opp. Spark Mall,
- New Delhi-110007, India.
- Email: <u>npcs.ei@gmail.com</u> , <u>info@entrepreneurindia.co</u>
- Tel: +91-11-23843955, 23845654, 23845886,
- Mobile: +91-9811043595, 8800733955
- Fax: +91-11-23845886
- Website : <u>www.entrepreneurindia.co</u> , <u>www.niir.org</u>
- Take a look at NIIR PROJECT CONSULTANCY SERVICES on #StreetView

https://goo.gl/VstWkd





# An ISO 9001:2015 Company



## Who are we?

- One of the leading reliable names in industrial world for providing the most comprehensive technical consulting services
- We adopt a systematic approach to provide the strong fundamental support needed for the effective delivery of services to our Clients' in India & abroad



We at NPCS want to grow with you by providing solutions scale to suit your new operations and help you reduce risk and give a high return on application investments. We have successfully achieved top-notch quality standards with a high level of customer appreciation resulting in long lasting relation and large amount of referral work through technological breakthrough and innovative concepts. A large number of our Indian, Overseas and NRI Clients have appreciated our expertise for excellence which speaks volumes about our commitment and dedication to every client's success.



We bring deep, functional expertise, but are known for our holistic perspective: we capture value across boundaries and between the silos of any organization. We have proven a multiplier effect from optimizing the sum of the parts, not just the individual pieces. We actively encourage a culture of innovation, which facilitates the development of new technologies and ensures a high quality product.



## What do we offer?

- Project Identification
- Detailed Project Reports/Pre-feasibility Reports
- Market Research Reports
- Business Plan
- Technology Books and Directory
- Industry Trend
- Databases on CD-ROM
- Laboratory Testing Services
- Turnkey Project Consultancy/Solutions
- Entrepreneur India (An Industrial Monthly Journal)



## How are we different ?

- We have two decades long experience in project consultancy and market research field
- We empower our customers with the prerequisite know-how to take sound business decisions
- We help catalyze business growth by providing distinctive and profound market analysis
- We serve a wide array of customers, from individual entrepreneurs to Corporations and Foreign Investors
- We use authentic & reliable sources to ensure business precision



# **Our Approach**

**Requirement collection** 

Thorough analysis of the project

Economic feasibility study of the Project

Market potential survey/research

**Report Compilation** 



# **Contact us**

## **NIIR PROJECT CONSULTANCY SERVICES**

106-E, Kamla Nagar, Opp. Spark Mall,

New Delhi-110007, India.

Email: <u>npcs.ei@gmail.com</u> , <u>info@entrepreneurindia.co</u>

Tel: +91-11-23843955, 23845654, 23845886,

Mobile: +91-9811043595, 8800733955

Fax: +91-11-23845886

Website : <u>www.entrepreneurindia.co</u> , <u>www.niir.org</u>

Take a look at NIIR PROJECT CONSULTANCY SERVICES on #StreetView

https://goo.gl/VstWkd







<u>https://www.linkedin.com/company/niir-project-</u> <u>consultancy-services</u>



<u>https://www.facebook.com/NIIR.ORG</u>



>https://www.youtube.com/user/NIIRproject



><u>https://twitter.com/npcs\_in</u>

<u>https://www.pinterest.com/npcsindia/</u>





